The von Hippel-Lindau (VHL) tumour suppressor gene encodes a substrate-specifying component of an E3 ubiquitin ligase that targets hypoxia-inducible factor (HIF) a subunits for degradation under normoxia. The VHL protein is composed of an N-terminal HIFa-binding b domain and a C-terminal a domain, which is necessary and sufficient for the formation of the E3 multiprotein enzyme. A large number of disease-causing mutations in either the a or b domain renders HIFa stable irrespective of oxygen tension, leading to the upregulation of numerous HIF-target genes, such as GLUT1 and VEGF. Here, we show that VHL forms a self-associated complex in vivo, but not in vitro, and demonstrate that coexpression of two different VHL missense mutants -one in the a domain and the other in the b domain -restores HIFmediated gene expression profile. These findings indicate that VHL homotypic complexes can function in vivo in a complementary fashion to target HIFa for ubiquitinmediated proteolysis, and potentially explain why VHLassociated tumours with a missense mutation-carrying VHL allele is almost invariably accompanied by a second VHL allele harbouring a gross truncation or deletion.
The von Hippel-Lindau (VHL) tumour suppressor gene encodes a substrate-specifying component of an E3 ubiquitin ligase that targets hypoxia-inducible factor (HIF) a subunits for degradation under normoxia. The VHL protein is composed of an N-terminal HIFa-binding b domain and a C-terminal a domain, which is necessary and sufficient for the formation of the E3 multiprotein enzyme. A large number of disease-causing mutations in either the a or b domain renders HIFa stable irrespective of oxygen tension, leading to the upregulation of numerous HIF-target genes, such as GLUT1 and VEGF. Here, we show that VHL forms a self-associated complex in vivo, but not in vitro, and demonstrate that coexpression of two different VHL missense mutants -one in the a domain and the other in the b domain -restores HIFmediated gene expression profile. These findings indicate that VHL homotypic complexes can function in vivo in a complementary fashion to target HIFa for ubiquitinmediated proteolysis, and potentially explain why VHLassociated tumours with a missense mutation-carrying VHL allele is almost invariably accompanied by a second VHL allele harbouring a gross truncation or deletion. Oncogene (2006 Oncogene ( ) 25, 3079-3083. doi:10.1038 ; published online 9 January 2006 Keywords: VHL; ECV; E3; HIF; homotypic association von Hippel-Lindau (VHL) disease is a rare autosomal dominant cancer syndrome that is caused by mutations in the VHL tumour-suppressor gene (Kaelin, 2002) . The VHL protein consists of two domains . The C-terminal a domain recruits Cul2, Rbx1 and elongin B via elongin C, which together forms the ECV (Elongins/Cul2/VHL) complex that functions as an E3 ubiquitin ligase to target proteins for polyubiquitylation (Kamura et al., 1999; Ohh et al., 1999; Stebbins et al., 1999) . Although several proteins have now been identified as potential substrates of ECV, the most well-characterized targets are the a subunits of hypoxiainducible factor (HIF) transcription factor. The physical interaction between ECV and HIFa is mediated through the b domain of VHL that specifically recognizes/binds to the oxygen-dependent-degradation domain (ODD) within HIFa (Ohh et al., 2000; Ivan et al., 2001; Jaakkola et al., 2001) . Moreover, oxygen-dependent hydroxylation of the evolutionarily conserved Proline residues within the ODD is critical for this interaction Maynard et al., 2003) . Under hypoxia, HIFa is no longer recognized by ECV and is rendered stable, allowing it to form a heterodimeric transcription factor with constitutively expressed and stable HIFb, and thereby triggering the transactivation of numerous hypoxia-inducible genes including vascular endothelial growth factor (VEGF), erythropoietin (EPO), and glucose transporter-1 (GLUT1) Ang et al., 2002) .
The vast majority of VHL disease-causing mutations map to either a or b domain of VHL and consequently disrupt ECV's ability to ubiquitylate HIFa (Kaelin, 2002) . The aberrant upregulation of HIF-target genes, many of which are proangiogenic, is thought to support the development of cancer (Kaelin, 2002) . In support, renal carcinoma cells expressing a mutant HIFa that escapes oxygen-dependent degradation have been shown to reacquire tumorigenic potential even in the presence of wild-type VHL (Kondo et al., 2002) . Thus, deregulation of HIFa appears to be one of the prevalent themes in the pathogenesis of VHL disease.
Interestingly, VHL-associated tumours very rarely harbour two different missense mutations -one on each VHL allele. In fact, a tumour containing a missense mutation in one VHL allele is invariably accompanied by a remaining allele with a gross truncation or that displays a loss of heterozygosity (Vortmeyer et al., 2002; Wait et al., 2004) . This raises the possibility that VHL functions in a complementary fashion where two VHL alleles with different missense mutations would generate products capable of 'rescuing' each other's defect. An individual with such mutations would, hypothetically, present as phenotypically normal.
In an effort to address the possibility of complementation, we asked whether VHL is capable of forming a homodimer. T7-tagged and HA-tagged VHL were in vitro translated, mixed, immunoprecipitated with an anti-HA antibody, and bound proteins separated on SDS-PAGE ( Figure 1a) . As expected, HA-VHL was present in the immunoprecipitate (Figure 1a , lower panel). However, T7-VHL did not co-precipitate with HA-VHL ( Figure 1a , top panel, lane 5). It is formally possible that in vitro translated HA-VHL had formed homodimers prior to the addition of the in vitro translated T7-VHL. To address this concern, we cotranslated the two proteins simultaneously and then performed anti-HA immunoprecipitation. However, no detectable T7-VHL co-precipitated with HA-VHL ( Figure 1a , top panel, lane 4). These results suggest that, at least in vitro, VHL proteins do not form dimers (or homotypic multimers).
We next asked whether VHL could self-associate in vivo. U2OS osteosarcoma cells were transiently transfected with plasmids encoding HA-VHL in combination with T7-VHL. Lysates were prepared, immunoprecipitated with anti-HA antibody, resolved on SDS-PAGE, and immunoblotted with anti-HA or anti-T7 antibody. T7-VHL was found to co-precipitate with HA-VHL ( Figure 1b , lane 4), indicating that the two differentially tagged VHLs bound each other. We asked whether this interaction occurred exclusively in intact cells prior to lysis or whether this interaction was simply a postlysis phenomenon. To address this concern, we first performed a competition assay where cells cotransfected with plasmids encoding T7-and HA-VHL were lysed using a lysis buffer containing increasing amounts of HA-VHL ( Figure 1b , lanes 5 and 6). Our prediction is that if homotypic VHL association occurs during postlysis then the amount of co-precipitating T7-VHL would decrease proportionately with the level of HA-VHL in the lysis buffer. However, the level of coprecipitating T7-VHL remained unchanged. In addition, cell lysates containing T7-VHL were mixed with lysates containing HA-VHL ( Figure 1b , lane 7). The mixed lysates immunoprecipitated with anti-HA antibody, while precipitating HA-VHL as expected, failed to coprecipitate T7-VHL. These results suggest that homotypic association of VHL occurs exclusively in intact cells prior to cell lysis.
To further validate the notion that VHL exists as a homotyic complex in vivo and to ascertain the functional consequence of such an interaction, we asked whether two different tumour-causing missense VHL mutants -one in the a domain and the other in the b domain -coexpressed in the same cell could rescue the other mutant's functional defect. As illustrated in Figure 2 , the a domain mutant R167Q is defective in forming an E3 ubiquitin ligase complex due to an inability to bind elongin C, whereas the b domain mutant Y112N is incapable of binding prolyl-hydroxylated HIFa (Bradley Although the two domains are functionally distinct, defects in either region abrogates the ability of VHL to ubiquitylate HIFa, leading to the stabilization of HIFa and transactivation of HIFtarget genes. Individual missense mutants such as R167Q and Y112N abolish ECV formation and HIFa binding, respectively. However, coexpression of these mutants would lead to a restoration of the HIFa pathway via heterotypic association between the two distinct VHL mutants effectively rescuing each other's functional defect.
et al., 1999; Ohh et al., 1999; Clifford et al., 2001) . Our homodimer-complementation model would predict that the association of R167Q to Y112N would result in a complex capable of recruiting the ECV components as well as binding HIFa for subsequent polyubiquitylation, thereby forming a functionally 'wild-type' VHL complex (Figure 2) .
To test this hypothesis, 786-O renal carcinoma cells devoid of VHL were stably transfected with mammalian expression plasmids encoding HA-VHL(WT), HA-VHL(Y112N), T7-VHL(R167Q), or empty plasmid (MOCK). Cells were then lysed and immunoprecipitated against the epitope tag. Bound proteins were resolved on SDS-PAGE and immunoblotted for VHL or elongin B, which is one of the components of the ECV complex ( Figure 3a) . As expected, while both VHL(WT) and the b domain VHL(Y112N) mutant coprecipitated elongin B, the a domain VHL(R167Q) coprecipitated a negligible level of elongin B (Figure 3a) . We next performed an in vitro VHL/HIF-1a(ODD) binding assay. In vitro translated HA-VHL(WT), HA-VHL(Y112N), and HA-VHL(R167Q) were generated, mixed with biotinylated-HIF-1a(ODD) peptide with either Proline 564 to Alanine substitution (P-A) or Proline 564 with an attached synthetic hydroxyl group (P-OH), pulled down with Streptavidin-coated protein A beads, and immunoblotted with an anti-HA antibody (Figure 3b) . VHL(Y112N) showed significantly diminished capacity to bind ODD(P-OH) compared to VHL(WT) or VHL(R167Q). Expectedly, ODD(P-A) failed to bind any VHL (Figure 3b) . Thus, VHL(Y112N) and VHL(R167Q) behaved, with respect to HIF regulation, as predicted in the model (see Figure 2 ). It should be noted that VHL(R167Q) bound less ODD(P-OH) compared to VHL(WT). This is consistent with certain alpha domain mutants (for example, C162F) that demonstrate attenuated capacity to bind HIF-a compared to their wild-type counterpart (Hoffman et al. (2001) and data not shown). It is thought that certain mutations in the alpha domain induce subtle conformational changes that affect the overall structure of VHL and thereby reduce the capacity of the beta domain to bind HIF. Furthermore, VHL(WT) supported in vitro ubiquitylation of 35 Slabeled Gal4-HIF-1a(ODD), while VHL(Y112N) and VHL(R167Q) independently (or in combination) failed to promote the ubiquitylation of Gal4-HIF-1a(ODD) (Figure 3c ). In addition, 786-O cells stably expressing either Y112N or R167Q showed an accumulation of hypoxia-inducible gene product, GLUT1 (a reliable marker of HIF activity), under normoxic conditions similar to cells devoid of VHL (Figure 3d) , indicating a genuine failure in HIF regulation.
We next addressed whether VHL(Y112N) and VHL(R167Q) could functionally complement each other to regulate HIF activity. U2OS cells were transiently transfected with plasmids encoding HA-VHL(WT), HA-VHL(Y112N), and HA-VHL(R167Q) with T7-VHL. Cells were then lysed, immunoprecipitated with anti-T7 antibody, and immunoblotted with anti-HA and anti-T7 antibodies (Figure 4a, lanes 2-6) . T7-VHL strongly co-precipitated all HA-VHL(WT, Y112N, and R167Q). Importantly, T7-VHL(R167Q) co-precipitated HA-VHL(Y112N) indicating that an a domain VHL mutant can complex with a b domain mutant (Figure 4a, lane 7) .
We have shown that 786-O cells stably expressing T7-VHL(R167Q) fail to recruit the rest of the ECV complex (see Figure 3a) . In contrast, when this same mutant is transiently expressed in U2OS cells, some Cul2 was found to co-precipitate with HA-VHL(R167Q) (Figure 4b , lane 5), suggesting that the ECV complex was formed, albeit to a lesser extent than HA-VHL(WT) or HA-VHL(Y112N) (Figure 4b, lanes 3 and 4) . The recruitment of the ECV complex by HA-VHL(R167Q) observed in U2OS cells is likely due to the physical association between VHL(R167Q) and endogenous VHL that is present in U2OS cells, but absent in 786-O cells. Therefore, the presence of endogenous wild-type VHL can restore ECV complex formation by VHL(R167Q) mutant.
Next, we asked whether the observed heterotypic association between VHL(Y112N) and VHL ( (Figure 4c ). HA-VHL(WT) and HA-VHL(Y112N), as expected, co-precipitated Cul2 (Figure 4c, second panel, lanes 2 and 3) . Importantly, while T7-VHL(R167Q) alone failed to co-precipitate Cul2, co-expression of HA-VHL(Y112N) with T7-VHL(R167Q) enabled co-precipitation of Cul2 via anti-T7 immunoprecipitation (Figure 4c, compare lanes  3 and 4) . To address whether the association of HA-VHL(Y112N) and T7-VHL(R167Q) was functionally competent to regulate HIF, the remaining one-half of the cell lysates were immunoprecipitated with anti-HA antibody and immunoblotted for HIF-2a (Figure 4c homodimer-complementation model of HIF regulation via self-association of VHL.
VHL-associated tumours rarely display two different missense VHL mutations -one on each allele -suggesting a possibility of functional complementation. Here, we demonstrate a scenario where if two missense mutations on separate functional domains (i.e., a and b domains) should occur, HIF regulation would remain unaffected. VHL is able to self-associate in vivo, but not in vitro. This explains why the introduction of in vitro translated VHL(Y112N) in combination with VHL(R167Q) failed to restore in vitro ubiquitylation of HIF-1a(ODD) (see Figure 3c , lane 5). The reason for the observed disparity is unclear, but it seems likely that certain modification(s)/processing is limited in vitro. Moreover, deletion of either a or b domain did not abolish homotypic association suggesting that the 'dimerization domain' is not an exclusive component of either a or b domain (data not shown). It is likely that there are multiple contact sites involved in dimerization of VHL. Of note, Ang et al. (2002) coexpressed Chuvash polycythemia-associated VHL(R200W) mutant with a truncated VHL and found comparable levels of EPO as compared to cells expressing VHL(R200W) alone. However, this is not surprising given that both proteins are defective in the same C-terminal region of VHL and thus, would not lead to a rescue of function. Although we have demonstrated that HIFa regulation can be rescued in a homotypic complementation manner, whether self-association is a prerequisite of E3-associated VHL function in vivo or whether other VHL functions, such as fibronectin matrix assembly , are subject to the same principle remain unknown.
